The presence of chronic arterial inflammation in response to atherogenic stimuli provides a framework in understanding the development and destabilization of atherosclerotic plaques. Oxidized lipids play a central role in mediating a variety of immune, pro-inflammatory, and plaquedestabilizing processes that further amplify inflammatory responses (1) . Underlying this inflammatory cascade is the production and secretion of cytokines, growth factors, and metalloproteinases, such as interleukin (IL)-1, tumor necrosis factor-a, and C-reactive protein (CRP) (2) . Genetic variations in the IL-1 gene family (chromosome 2q13 region), which include the pro-inflammatory cytokines IL-1a and IL-1b, and the anti-inflammatory IL-1 receptor antagonist (IL-1Ra) (3) (4) (5) , are commonly found in the human population, affect proinflammatory gene regulation (6) , and have been associated with elevated levels of pro-inflammatory mediators (7) (8) (9) (10) . The interplay of various single-nucleotide polymorphisms (SNPs) within this IL-1 family determines the overall net effect on proor anti-inflammatory responses.
The majority of published studies have shown an association of IL-1 and cardiovascular disease, including early myocardial infarction (MI)/acute coronary syndromes (8, (11) (12) (13) (14) (15) (16) , coronary artery disease (CAD) (17) (18) (19) (20) , acute ischemic stroke (21) (22) (23) , restenosis following coronary stenting (24) , and venous thrombosis (25) . CANTOS (the Canakinumab Antiinflammatory Thrombosis Outcomes Study) (26) will test the hypothesis that treating patients with persistent elevation of CRP post-MI with a human monoclonal antibody that neutralizes IL-1b antibody will reduce cardiovascular events.
Oxidized phospholipids (OxPLs) are pro-inflammatory (27) , mediate atherothrombosis, and are abundant in pathologically defined human vulnerable plaques (28) . Plasma levels of specific OxPL on apolipoprotein B-100 particles (OxPL/apoB) are elevated in patients with coronary, carotid, and peripheral artery disease (29) , as well as in those with acute coronary syndromes (30) , and following percutaneous coronary intervention (31) . Importantly, they predict the occurrence of cardiac death, MI, and stroke in unselected populations (32) (33) (34) . Additionally, they reclassify up to one-third of patients in intermediate Framingham risk categories into either higher or lower categories (33) . In human plasma, OxPLs are preferentially carried by lipoprotein (Lp) (a) compared with other apoB-100 particles (reviewed in Taleb et al. [35] ). OxPLs are also covalently bound by plasminogen, but early data suggest different pathophysiological implications when OxPLs are on Lp(a) versus plasminogen (36) .
Because OxPL mediate pro-inflammatory responses on endothelial cells and monocytes/macrophages (27) , it is possible that the risk they confer on atherothrombosis is potentiated by genetic predisposition to inflammation. In the present study, we hypothesized that the risk for CAD conferred by OxPL/apoB and Lp(a) may be influenced by IL-1 genotypes known to be associated with enhanced inflammatory responses.
Methods
Study design. A full description of the methods is available in the Online Appendix. The study was prospectively designed to test the association of CAD with specific IL-1 genotype groups known to be associated with higher inflammatory responses. The study design has been described previously in detail (37) . Briefly, 504 eligible, consecutive patients undergoing clinically indicated coronary angiography were recruited. We focused our analyses on angiographically significant disease, defined as diameter stenosis >50%. Two patients had incomplete OxPL/apoB data, and 3 patients had incomplete IL-1 data; therefore, 499 patients were available for the present analysis. Four hundred sixty-six patients (92.5%) were followed for up to 4.0 years (interquartile range: 3.9 to 4.2 years). The follow-up events consisted of 20 deaths (6 cardiac), 14 MIs, 26 coronary revascularizations (15 percutaneous intervention only, 9 coronary artery bypass surgery only, and 2 with both), and 10 strokes. Genetic analyses. SNPs were genotyped at 1 locus in the gene for IL-1a (IL1A[þ4845] , rs17561, G > T) and at 2 loci in the gene for IL-1b (IL1B[þ3954], rs1143634, C > T; and IL1B[À511], rs16944, C > T]) (38) . IL-1 composite genotype patterns used for association with biochemical and clinical parameters. We designed the study to evaluate the relationship between CAD and IL-1 genotypes that are associated with differential expression of IL-1b. Four SNPs in the promoter region of IL1B have been shown to be functional at the molecular level and operate in haplotype context to alter transcriptional activity of IL-1b (6) . The functional IL1B SNPs define 4 predominant haplotypes that, as pairs observed together, account for significantly different clinical levels of IL-1b protein in tissue fluid samples (10) . All possible composite genotype combinations of the 3 SNPs used in the study provided an efficient tagging of the composite genotypes resulting from combinations of the functional IL1B promoter haplotypes that define differential expression of IL1b protein (10) . Table 1 shows the composite genotypes in this study that defined the IL-1(þ) group, which are associated with overexpression of IL-1b, and the IL-1(-) group, which are the composite genotypes that have not been associated with overexpression of IL-1b. The IL-1(þ) Tsimikas et al. May 6, 2014 May 6, :1724 Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease and IL-1(-) groups were defined and published before data analysis (39) .
Results
Baseline characteristics of the study group. (24) 71 (24) 51 (26) Mild 109 (22) 68 (23) 41 (21) 1-vessel 84 (17) 46 (15) 38 (19) 2-vessel 80 (16) 50 (17) 30 (15) 3-vessel 104 (21) 64 (21) 40 ( 
T* indicates that the second allele in the genotype can be either a G or a T. yIndicates that the genotype at that locus can be GG, GT, or TT.
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Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease 0.71). In patients age >60 years, the association between OxPL/apoB levels and risk for CAD was not significant in either IL-1(þ) or IL-1(-) patients (Table 3) . Similar to the OxPL/apoB results, the association between Lp(a) and the risk for CAD was observed primarily in IL-1(þ) patients, with the strongest genotype effect present in patients 60 years of age (OR: 9.00; 95% CI: 3.00 to 27.03; p < 0.001) ( Table 4) .
Interaction tests were performed comparing IL-1(þ) patients to IL-1(-) patients. p Values for the interaction of OxPL/apoB were 0.007 for IL-1(þ) versus IL-1(-) patients 60 years of age, and 0.70 for IL-1(þ) versus IL-1(-) patients >60 years of age. p Values for the interaction of Lp(a) were 0.019 for IL-1(þ) versus IL-1(-) patients 60 years of age and p ¼ 0.77 for IL-1(þ) versus IL-1(-) patients >60 years of age. Multivariate analysis of CAD risk in the different genetic strata. Multivariate logistic regression analysis was performed to adjust for factors known to affect the risk for CAD. Figure 1 shows ORs for sex, OxPL/apoB, hsCRP, current smoking, low-density lipoprotein cholesterol (LDL-C), hypertension, triglycerides, Lp(a), and high-density lipoprotein cholesterol (HDL-C) when all were included in a single logistic binary regression model. In patients 60 years of age and IL-1(þ), male sex (p ¼ 0.001), OxPL/apoB (per doubling) (p ¼ 0.010), and hsCRP (log2) (p ¼ 0.004) were Tsimikas et al.
Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease May 6, 2014 May 6, :1724 independent predictors of CAD, whereas Lp(a) was not a significant predictor (Fig. 1A) . The association of OxPL/ apoB (OR: 1.83; 95% CI: 1.10 to 3.05; p ¼ 0.02) to CAD remained similar without hsCRP in the model. When the 44 patients with MI within 60 days before coronary angiography were excluded, the data remained qualitatively similar, except that hsCRP was no longer a predictor of CAD (OR: 1.23; 95% CI: 0.89 to 1.68; p ¼ 0.21). Baseline hsCRP levels in these patients were significantly elevated compared with those in patients without MI, as described previously (33) . In patients 60 years of age and IL-1(-), male sex (p ¼ 0.007), LDL-C (p ¼ 0.005), and hypertension (p ¼ 0.014) were independent predictors (Fig. 1B) .
In patients >60 years of age and IL-1(þ), male sex (p < 0.001) and HDL-C (p ¼ 0.05) were independent predictors of CAD, but not OxPL/apoB (Fig. 2A) . In patients age >60 years and IL-1(-), male sex (p ¼ 0.004) and hypertension (p ¼ 0.017) were associated with higher risk (Fig. 2B) .
To further explore the relationship between OxPL/apoB or Lp(a) levels and IL-1 genotype relative to the risk for CAD, we stratified patients by IL-1 genotype and developed regression models to assess the relationship of OxPL/apoB and Lp(a) levels to CAD risk. The relationships of the OR values for CAD are expressed as functions of the magnitudes of differences in OxPL/apoB and Lp(a) levels in IL-1(þ) 
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Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease and IL-1(-) patients. The OR for CAD was highly sensitive to differences in levels of both OxPL/apoB and Lp(a) in IL-1(þ) patients, but no association was present in IL-1(-) patients (Fig. 3) . IL-1 genotype effect on OxPL risk for CAD and CRP levels. Because some of the IL-1 genetic variations included in the genetic patterns used in this study have been previously associated with elevated CRP (7,10), we evaluated whether the IL-1 genotype influence on the OxPL association with CAD was influenced by hsCRP levels. The relationship of OxPL/apoB to CAD in IL-1(þ) patients 60 years of age was analyzed in the multivariate logistic regression framework in patients with hsCRP above and below the median hsCRP level in this study population (2.86 mg/l). The OR for the OxPL/apoB association with CAD in IL-1(þ) patients with hsCRP >2.86 mg/l was 3.36 (95% CI: 1.21 to 9.40; p ¼ 0.02), and in those with hsCRP <2.86 mg/l, the OR was 1. Relationship of IL-1 genotype to age at presentation to the cardiac catheterization laboratory. Having established the relationship of OxPL/apoB and Lp(a) with CAD in IL-1(þ), but not IL-1(-), patients, particularly those at a younger age, we evaluated whether age at the time of cardiac catheterization was related to IL-1 composite genotype. IL-1(þ) patients above the median of OxPL/apoB presented to the cardiac catheterization laboratory a mean of 3.9 years earlier than did IL-1(-) patients (mean age at presentation 58.0 vs. 61.9 years; p ¼ 0.006). Similarly, IL-1(þ) patients above the median of Lp(a) presented a mean of 3.5 years earlier than did IL-1(-) patients (mean: 58.8 vs. 62.1 years; p ¼ 0.019). In contrast, there was no significant IL-1 genotype effect on age at presentation to the cardiac catheterization laboratory in patients below the median of OxPL/apoB (mean: 58.9 vs. 60.7 years; p ¼ 0.18) or Lp(a) (mean: 58.7 vs. 59.9; p ¼ 0.40). Relationship of IL-1 genotype to CAD events. In the overall group, cardiovascular events were not significantly different between IL-1(þ) and IL-1(-) patients (p ¼ 0.56). Tsimikas et al.
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Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease May 6, 2014 May 6, :1724 However, Kaplan-Meier curves revealed that IL-1(þ) patients with OxPL/apoB above the median had the worst 4-year event-free survival (composite of death, MI, stroke, and need for revascularization) (p ¼ 0.002 compared with the other 3 groups) (Fig. 4A) . The p value among the 4 groups for death was 0.069 and for death/MI was 0.016. The interaction test for IL-1 group by OxPL/apoB group was p ¼ 0.002 for event-free survival. For Lp(a), IL-1(þ) patients with Lp(a) above the median exhibited worst 4-year event-free survival (p ¼ 0.034 compared with the other 3 groups) (Fig. 4B) . The p value among the 4 groups for death was 0.054 and for death/MI was 0.011. The interaction test for IL-1 group by Lp(a) group was p ¼ 0.014 for event-free survival. There were not enough events to analyze by age cutoffs.
Discussion
This study demonstrates that genetic differences in the IL-1 gene cluster, known to be associated with inflammatory responsiveness, strongly influence the presence of angiographically determined CAD and CAD events mediated by OxPL/apoB and Lp(a). Patients with pro-inflammatory IL-1(þ) genotypes were at a continuum of risk for the presence of CAD, whereas patients with IL-1(-) genotypes seemed to be insensitive to the risk for CAD mediated by increasing OxPL/apoB or Lp(a) levels. These findings were accentuated in subjects with elevated hsCRP levels. This study provides evidence of a biological link between genetic predisposition to inflammation, oxidation of phospholipids, and genetically mediated elevated Lp(a) levels. It also highlights a possible effect of specific genetic factors in accelerating atherogenesis, development of CAD on angiography, and mediation of cardiovascular events.
The genes encoding the pro-inflammatory cytokines IL-1a and IL-1b are among the first to be activated in the course of an inflammatory response and play a major role in both acute and chronic inflammation (4) . Plasma levels of IL-1a and IL-1b show reproducible interindividual differences. Furthermore, IL-1 genetic patterns that are highly prevalent in the population, 60% of the white population, as noted in this study, have been associated with variations in the levels or expression of IL-1a (40), IL-1b (8) , and the endogenous antagonist, IL-1Ra (41). The IL-1 composite genotypes used in this study were derived from combinations of the predominant functional haplotypes in the promoter region of the gene for IL-1b (6) and other SNPs in the IL-1a and b genes that have been associated with pro-inflammatory responses (10, 42) . IL-1b haplotypes exhibit allele-specific differences in nuclear protein binding and transcription rates (6) . IL-1(þ) genotypes are associated with enhanced generation of IL-1b when mononuclear cells are stimulated (8) and have been associated with higher IL-1b levels in plasma (41) . Some of the 3 composite genotypes that compose the IL-1(þ) pattern for this study have been associated with significantly elevated hsCRP levels in plasma compared with the IL-1(-) pattern (7, 8, 10, 43, 44) . It should be noted that although the IL-1 genotype association with elevated IL1b expression is also significant in gastric mucosa, the genotypes associated with elevated expression appear to be different from those reported for peripheral blood mononuclear cells (45, 46) . IL-1Ra is an important component of the net IL-1 biological activity of this system, as signaled through the IL-1 receptor type 1, and has been implicated in atherosclerotic cardiovascular diseases (3) . Variants in the gene for IL-1Ra (IL1RN) have been associated with lower expression and circulating levels of IL-1Ra (9, 47, 48) and with cardiovascular disease outcomes in some, but not all, studies (14, 20, 49) . Several variants in IL1RN and other genes in the IL-1 cluster on chromosome 2q13-14 are in linkage disequilibrium with the specific IL1A and IL1B markers used in this study. For example, in a population cohort of 839 unrelated white patients who tested positive Tsimikas et al. May 6, 2014 May 6, :1724 Interleukin-1 Genetics, Oxidized Phospholipids, and Coronary Disease for the IL-1 genotype patterns used in the current study, 64.5% were also homozygous for the T allele of IL1RN (þ2018, rs419598) compared with 35 .0% of those who tested negative. Future studies with larger datasets may allow for the analysis of contributions by other variants in the IL-1 region, in light of the strong linkage disequilibrium.
Vascular wall cells, such as endothelial cells and smooth muscle cells, as well as macrophages and monocytes, can produce IL-1b and IL-1Ra, and these cytokines are also present in human atherosclerotic lesions (3, 17, 19, 50) . It has been shown that IL-1b promoter haplotype pairs are associated with higher levels of IL-1b in plasma and from stimulated peripheral blood monocytes from patients, as well as elevated levels of CRP (10) . In addition, the IL-1(þ) genotype patterns used in the current study tag haplotypes that include the T allele of IL1A(-889, rs1800587), which has been shown to alter transcription factor binding sites in the IL1A gene (51) and was associated with increased levels of IL-1a protein in human gingival fluid samples (40) . Transgenic mouse models with variations in IL-1 genotypes further support the causal role of IL-1 in atherogenesis (reviewed by Fearon and Fearon [3] and Ridker et al. [26] ). In IL1RA knockout mice, unopposed IL-1 biological activity resulted in spontaneous arterial inflammation with massive infiltration of macrophages and CD4 þ , interferon g þ T cells at branch points in intermediate and large arteries (52, 53) . Decreases in IL-1 biological activity in apoE-deficient mice decreased the rate and extent of atherosclerosis formation (54, 55) . By contrast, increases in IL-1 activity increased atherosclerotic lesion size with more macrophages within lesions (56) . Furthermore, anakinra, a recombinant form of human IL1Ra, improves vascular function in patients with rheumatoid arthritis (57) .
In experimental studies, oxidized phospholipids interact with cells in the vessel wall and promote pro-inflammatory and pro-atherogenic properties. For example, in a largescale gene-expression analysis involving 9,600 complementary deoxyribonucleic acid targets, IL1B was one of the differentially overexpressed genes when macrophages were loaded with oxidized low-density lipoprotein (OxLDL), which is known to be enriched in OxPL detected by E06, compared with acetylated-LDL loading (58) . OxLDL stimulation of coronary artery smooth muscle cells also led to significant overexpression of IL-1b (59). More specifically, stimulation of endothelial cells and macrophages with OxPL leads to prominent expression of IL-1a and IL-1b (60, 61) , and in turn, stimulation of endothelial cells with IL-1b leads to the generation of such OxPLs (62) . Thus, it is reasonable to hypothesize that the polymorphisms of the IL-1 family might influence the expression of inflammatory responses to OxPL. Indeed, supporting data show that IL-1 genetic variations have been associated with acute coronary events, CAD, and stroke (11-16,20-23,25,57,63,64) .
In clinical studies, elevated OxPL/apoB levels have predicted new CVD events (29, 33, 35, 65) . This study has expanded our understanding of the underlying mechanisms behind this risk by showing that the enhanced risk for CAD and CAD events mediated by OxPL/apoB and Lp(a) is particularly potent in IL-1(þ) patients. Interestingly, this risk for CAD persisted despite Lp(a) in the present model, suggesting that in certain patient populations, such as patients <60 years of age, OxPL/apoB may be a better predictor than Lp(a). Patients with an underlying genetic predisposition to inflammation and dyslipidemia have exposure to cardiovascular risk from birth, which may explain why IL-1(þ) patients 60 years of age with elevated Lp(a) and OxPL/apoB levels are at a particularly elevated risk for premature CAD. Consistent with the role of lifelong exposure to a genetic predisposition to inflammation and genetically determined Lp(a) levels, it was demonstrated in this study that IL-1(þ) patients with Lp(a) or OxPL/apoB levels above the median presented for coronary angiography several years earlier than did those in the lowest quartiles.
It is noteworthy that in this population, the IL-1 genotype effect on the risk for CAD was more pronounced in patients above the median of hsCRP, a biomarker of inflammation generated secondary to cytokines such as IL-6 and IL-1. Similarly, the LPA gene contains an IL-6 response element (66) , and patients with inflammatory disorders such as rheumatoid arthritis have elevated Lp(a) levels, which are reduced on treatment with the IL-6Ra antibody tocilizumab (67, 68) . The CANTOS trial will be instrumental in testing whether inhibition of inflammatory responses leads to a lower rate of cardiovascular events. The data from this study suggest that patients with the IL-1(þ) genotype and elevated OxPL/apoB and/or Lp(a) levels are a particularly high-risk subset that may maximally benefit from therapies aimed at inhibiting IL-1b and IL-1a responses. Study limitations. Limitations of this study included that patients were selected from a population referred for coronary angiography for clinical indications and thus the data may not be generalizable to broader populations. This study also included predominantly white patients whose IL-1 genotypes and genetic associations may differ from those of other ethnic groups, and it will be important to study these associations in other populations.
Conclusions
This study suggests that the previously demonstrated contribution of OxPL/apoB and Lp(a) on angiographically documented CAD and CAD events is conditional on proinflammatory IL-1 genotypes. This novel paradigm links the etiology of atherogenesis attributed to OxPL and Lp(a) from genetics to clinical expression of CAD. If confirmed and validated in prospective populations, these findings may 
